First Chinese Patent for pSivida Limited

11-May-2005

pSivida Limited announced that it has been granted its first patent in China. This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil(tm). The potential lower cost of the Chinese registration pathway and the vast need of BrachySil(tm)-like products make China an important commercial target.

pSivida is currently in exploratory discussions with commercialisation partners for the Chinese market for its lead product BrachySil(tm) and is investigating the optimum regulatory process to launch this product in China. It is expected that pSivida would enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing.

Chinese Patent Number ZL 99807447.0 provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery. This invention was based on the demonstration in model systems, that long term BioSilicon(tm) implants lack toxicology and degrade in the body in a controllable manner. It also claims the loading of BioSilicon(tm) implants of varying porosity and structure with different drugs.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances